PPA
ELDN icon

Parametric Portfolio Associates’s Eledon Pharmaceuticals ELDN Stock Holding History

Parametric Portfolio Associates’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-743
Closed -$67K – 3896
2018
Q1 		$67K Buy
+743
New +$54.7K ﹤0.01% 3890
2015
Q2 		– Sell
-124
Closed -$228K – 3964
2015
Q1 		$228K Buy
+124
New +$274K ﹤0.01% 3697

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DC
Derby & Company Newton, Massachusetts $495M AUM 23.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Parametric Portfolio Associates's ELDN Position: Q2 2018 in Review

Parametric Portfolio Associates sold out of Eledon Pharmaceuticals (ELDN) in Q2 2018, closing a stake of 743 shares — an estimated $67K sold.

Parametric Portfolio Associates first reported a position in ELDN in Q1 2015 and held it in 2 quarters. The position peaked at $228K in Q1 2015. 16 funds tracked by Wall St. Rank hold ELDN as of Q2 2018.

  • Parametric Portfolio Associates reported no remaining Eledon Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Parametric Portfolio Associates sold 743 Eledon Pharmaceuticals shares in Q2 2018, an estimated $67K.
  • Parametric Portfolio Associates first reported a position in Eledon Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Parametric Portfolio Associates's Eledon Pharmaceuticals position peaked at $228K in Q1 2015.
  • 16 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2018.

Based on Parametric Portfolio Associates's 13F filing for Q2 2018, filed 13 Aug 2018.